Draetta, Giulio F.

Cyclin D1 is a nuclear protein required for cell cycle progression in G1

Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development

Cancer-related Molecular PathwaysSignaling Pathways in Disease

Cited by 1,614

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 1,259

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine

Cancer, Hypoxia, and MetabolismMitochondrial Function and Pathology

Cited by 928

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell

Hippo pathway signaling and YAP/TAZPancreatic and Hepatic Oncology Research

Cited by 716

Genetics and biology of pancreatic ductal adenocarcinoma

Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 527

Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage

Busino, L., Donzelli, M., Chiesa, M., Guardavaccaro, D., Ganoth, D., Valerio Dorrello, N., Hershko, A., Pagano, M., & Draetta, G. F. (2003) · Nature

DNA Repair MechanismsUbiquitin and proteasome pathways

Cited by 447

Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts

Pagano, M., Theodoras, A. M., Tam, S. W., & Draetta, G. F. (1994) · Genes & Development

DNA Repair MechanismsCancer-related Molecular Pathways

Cited by 294

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

Vangamudi, B., Paul, T. A., Shah, P. K., Kost-Alimova, M., Nottebaum, L., Shi, X., Zhan, Y., Leo, E., Mahadeshwar, H. S., Protopopov, A., et al. (2015) · Cancer Research

Chromatin Remodeling and CancerProtein Degradation and Inhibitors

Cited by 281

Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer

Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature

Cancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology Research

Cited by 264

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

Zhang, L., Yao, Y., Zhang, S., Liu, Y., Guo, H., Ahmed, M., Bell, T., Zhang, H., Han, G., Lorence, E., et al. (2019) · Science Translational Medicine

Cancer, Hypoxia, and MetabolismLymphoma Diagnosis and Treatment

Cited by 233

Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer

Yao, W., Rose, J. L., Wang, W., Seth, S., Jiang, H., Taguchi, A., Liu, J., Yan, L., Kapoor, A., Hou, P., et al. (2019) · Nature

Pancreatic and Hepatic Oncology ResearchProteoglycans and glycosaminoglycans research

Cited by 214

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor

Palmer, W. S., Poncet-Montange, G., Liu, G., Petrocchi, A., Reyna, N., Subramanian, G., Theroff, J., Yau, A., Kost-Alimova, M., Bardenhagen, J. P., et al. (2016) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsHistone Deacetylase Inhibitors Research

Cited by 168

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature

Pancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis

Cited by 131

PRKCI promotes immune suppression in ovarian cancer

Sarkar, S., Bristow, C. A., Dey, P., Rai, K., Perets, R., Ramirez-Cardenas, A., Malasi, S., Huang-Hobbs, E., Haemmerle, M., Wu, S. Y., et al. (2017) · Genes & Development

Ovarian cancer diagnosis and treatmentHippo pathway signaling and YAP/TAZ

Cited by 93

YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma

Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., et al. (2019) · JCI Insight

Hippo pathway signaling and YAP/TAZPancreatic and Hepatic Oncology Research

Cited by 75

Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers

Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine

Protein Kinase Regulation and GTPase SignalingHippo pathway signaling and YAP/TAZ

Cited by 6